<img src="https://publish-01.obsidian.md/access/744ac39d33cabbc297b91373bfcac24d/bin/images/Switzerland_map.png" alt="Switzerland" class="page-header-sidebar-image"> Switzerland has provisions in its legislation relating to the granting of compulsory licences. These can be found in Arts. 36-40e of the Federal Act on Patents for Inventions. According to Art. 40e of the Patents Act, a compulsory licence may only be granted if efforts by the applicant to obtain a contractual licence on appropriate market terms within a reasonable period of time have been unsuccessful. In the case of a compulsory licence in accordance with Art. 40d (i.e. a compulsory licence for the manufacture and export of pharmaceutical products to countries with insufficient production capacities), a period of 30 working days is regarded as reasonable. More information can be found [here](https://e-courses.epo.org/wbts_int/CompulsoryLicensing/CL_CH.pdf). ## Compulsory licences Switzerland has been requested to issue a compulsory licence for [[Pertuzumab]] by Public Eye. The compulsory licence has not been issued because the application is still pending. ## Generic manufacturers Switzerland has its own generic manufacturer: [InterGenerika](https://www.intergenerika.ch/).